In the context of solid tumors, unbalanced E2F1 regulation can lead to the emergence of aggressive tumor cells, which drive cancer progression, resistance to anti-cancer drugs, and the rise of metastatic lesions9–13. The gene discussed is E2F1; the disease is cancer.